RESUMEN
Objective:To observe influence of benazepril combined trimetazidine on blood levels of follistatin-like 1 (FSTL1)and platelet activating factor (PAF)and vascular endothelial function in patients with coronary heart dis-ease (CHD)complicated heart failure (HF).Methods:A total of 120 CHD patients with chronic heart failure were selected from our hospital.They were randomly and equally divided into benazepril group and combined treatment group (received benazepril combined trimetazidine therapy),both groups were treated for six months.Serum Blood levels of N-terminal pro brain natriuretic peptide (NT-proBNP),FSTL1 and PAF,endothelial progenitor cells (EPCs)count and fore brachial artery endothelium dependent diastolic-systolic function (FMD)before and after treatment were measured and compared between two groups.Results:Compared with before treatment,there were significant rise in left ventricular ejection fraction (LVEF),6min walking distance (6MWD),EPCs and FMD,and significant reductions in serum levels of NT-proBNP,FSTL1 and PAF after treatment in two groups,P <0.05 or <0.01;compared with benazepril group,there were significant rise in LVEF [(41.94±9.19)% vs.(46.15±10.04)%], 6MWD [(333.94±58.29)m vs.(383.14±77.84)m],EPCs [(0.059±0.029)pg/ml vs.(0.083±0.014)pg/ml]and FMD [(7.53±2.02)% vs.(8.24±1.42)%],and significant reductions in serum levels of NT-proBNP [(2.74±0.69) ng/ml vs.(2.05±0.34)ng/ml],FSTL1 [(5.38±1.29)ng/ml vs.(4.64±0.84)ng/ml]and PAF [(5.16±0.92)μg/ml vs.(4.20±1.05)μg/ml]in combined treatment group,P <0.05 or <0.01.Conclusion:Benazepril combined trimeta-zidine can effectively reduce blood levels of NT-proBNP,FSTL1 and PAF,and promote vascular endothelial function re-covery in patients with coronary heart disease complicated chronic heart failure.
RESUMEN
Objective:To observe influence of benazepril combined trimetazidine on blood levels of follistatin-like 1 (FSTL1)and platelet activating factor (PAF)and vascular endothelial function in patients with coronary heart dis-ease (CHD)complicated heart failure (HF).Methods:A total of 120 CHD patients with chronic heart failure were selected from our hospital.They were randomly and equally divided into benazepril group and combined treatment group (received benazepril combined trimetazidine therapy),both groups were treated for six months.Serum Blood levels of N-terminal pro brain natriuretic peptide (NT-proBNP),FSTL1 and PAF,endothelial progenitor cells (EPCs)count and fore brachial artery endothelium dependent diastolic-systolic function (FMD)before and after treatment were measured and compared between two groups.Results:Compared with before treatment,there were significant rise in left ventricular ejection fraction (LVEF),6min walking distance (6MWD),EPCs and FMD,and significant reductions in serum levels of NT-proBNP,FSTL1 and PAF after treatment in two groups,P <0.05 or <0.01;compared with benazepril group,there were significant rise in LVEF [(41.94±9.19)% vs.(46.15±10.04)%], 6MWD [(333.94±58.29)m vs.(383.14±77.84)m],EPCs [(0.059±0.029)pg/ml vs.(0.083±0.014)pg/ml]and FMD [(7.53±2.02)% vs.(8.24±1.42)%],and significant reductions in serum levels of NT-proBNP [(2.74±0.69) ng/ml vs.(2.05±0.34)ng/ml],FSTL1 [(5.38±1.29)ng/ml vs.(4.64±0.84)ng/ml]and PAF [(5.16±0.92)μg/ml vs.(4.20±1.05)μg/ml]in combined treatment group,P <0.05 or <0.01.Conclusion:Benazepril combined trimeta-zidine can effectively reduce blood levels of NT-proBNP,FSTL1 and PAF,and promote vascular endothelial function re-covery in patients with coronary heart disease complicated chronic heart failure.